Noninvasive detection of any-stage cancer using free glycosaminoglycans.

ABSTRACT: Cancer mortality is exacerbated by late-stage diagnosis. Liquid biopsies based on genomic biomarkers can noninvasively diagnose cancers. However, validation studies have reported ~10% sensitivity to detect stage I cancer in a screening population and specific types, such as brain or genitourinary tumors, remain undetectable. We investigated urine and plasma free glycosaminoglycan profiles (GAGomes) as tumor metabolism biomarkers for multi-cancer early detection (MCED) of 14 cancer types using 2,064 samples from 1,260 cancer or healthy subjects. We observed widespread cancer-specific changes in biofluidic GAGomes recapitulated in an in vivo cancer progression model. We developed three machine learning models based on urine (N_urine = 220 cancer vs. 360 healthy) and plasma (

SUBMITTER: Bratulic S 

PROVIDER: S-EPMC9897435 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature